Final Results of Phase III SYMMETRY Study: Randomized, Double-Blind Trial of Elesclomol Plus Paclitaxel Versus Paclitaxel Alone As Treatment for Chemotherapy-Naive Patients With Advanced Melanoma

Phase III, open-label, randomized, comparative study of tremelimumab (CP-675,206) and chemotherapy (temozolomide [TMZ] or dacarbazine [DTIC]) in patients with advanced melanoma

(2017) A. Ribas et al.   JOURNAL OF CLINICAL ONCOLOGY

Alteration of the epigenome during carcinogenesis of intestinal-type gastric cancer.

(2017) Yong Sung Kim et al.   JOURNAL OF CLINICAL ONCOLOGY

The oncology drug elesclomol selectively transports copper to the mitochondria to induce oxidative stress in cancer cells

(2012) Masazumi Nagai et al.   FREE RADICAL BIOLOGY AND MEDICINE

Randomized, Double-Blind, Placebo-Controlled Phase III Trial Comparing Docetaxel and Prednisone With or Without Bevacizumab in Men With Metastatic Castration-Resistant Prostate Cancer: CALGB 90401

(2012) William Kevin Kelly et al.   JOURNAL OF CLINICAL ONCOLOGY

Mitochondrial Electron Transport Is the Cellular Target of the Oncology Drug Elesclomol

(2012) Ronald K. Blackman et al.   PLoS One

Extended schedule, escalated dose temozolomide versus dacarbazine in stage IV melanoma: Final results of a randomised phase III study (EORTC 18032)

(2011) Poulam M. Patel et al.   EUROPEAN JOURNAL OF CANCER

Randomized, Placebo-Controlled, Phase III Study of Oxaliplatin, Fluorouracil, and Leucovorin With or Without PTK787/ZK 222584 in Patients With Previously Treated Metastatic Colorectal Adenocarcinoma

(2011) Eric Van Cutsem et al.   JOURNAL OF CLINICAL ONCOLOGY

Randomized, Placebo-Controlled, Phase III Study of First-Line Oxaliplatin-Based Chemotherapy Plus PTK787/ZK 222584, an Oral Vascular Endothelial Growth Factor Receptor Inhibitor, in Patients With Metastatic Colorectal Adenocarcinoma

(2011) J. Randolph Hecht et al.   JOURNAL OF CLINICAL ONCOLOGY

Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation

(2011) Paul B. Chapman et al.   NEW ENGLAND JOURNAL OF MEDICINE

Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma

(2011) Caroline Robert et al.   NEW ENGLAND JOURNAL OF MEDICINE

Endoscopic Diagnosis of Childhood Burkitt's Lymphoma of the Colon

(2010) Frédéric Millot et al.   JOURNAL OF CLINICAL ONCOLOGY

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

(2010) F. Stephen Hodi et al.   NEW ENGLAND JOURNAL OF MEDICINE

Current systemic therapy for metastatic melanoma

(2009) Sanjiv S Agarwala   Expert Review of Anticancer Therapy

Phase II, Randomized, Controlled, Double-Blinded Trial of Weekly Elesclomol Plus Paclitaxel Versus Paclitaxel Alone for Stage IV Metastatic Melanoma

(2009) Steven O'Day et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase III Trial of Bevacizumab in Combination With Gemcitabine and Erlotinib in Patients With Metastatic Pancreatic Cancer

(2009) Eric Van Cutsem et al.   JOURNAL OF CLINICAL ONCOLOGY

Vaccine trials in melanoma—time for reflection

(2009) Alexander M. M. Eggermont   Nature Reviews Clinical Oncology

Reactive oxygen species: an Achilles’ heel of melanoma?

(2008) John P Fruehauf et al.   Expert Review of Anticancer Therapy

Elesclomol induces cancer cell apoptosis through oxidative stress

(2008) J. R. Kirshner et al.   MOLECULAR CANCER THERAPEUTICS